NASDAQ:DXCMDexCom Stock Price, Forecast & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding DexCom, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add $378.70 +0.39 (+0.10 %) (As of 06/1/2020 04:00 PM ET) Add Compare Share Today's Range$372.12Now: $378.70▼$383.8850-Day Range$273.26MA: $360.22▼$421.3652-Week Range$118.42Now: $378.70▼$428.59Volume776,959 shsAverage Volume1.54 million shsMarket Capitalization$34.97 billionP/E Ratio238.18Dividend YieldN/ABeta0.76 ProfileAnalyst RatingsAdvanced ChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsSocial Media DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company offers its systems for ambulatory use by people with diabetes; and for use by healthcare providers. Its products include DexCom G6, a CGM system for diabetes management; DexCom G5 mobile CGM system to communicate directly to patient's mobile device; DexCom G4 PLATINUM system for continuous use by adults with diabetes; and DexCom Share, a remote monitoring system. DexCom, Inc. has a collaboration and license agreement with Verily Life Sciences LLC and Verily Ireland Limited to develop a series of next-generation CGM products. The company markets its products directly to endocrinologists, physicians, and diabetes educators. DexCom, Inc. was founded in 1999 and is headquartered in San Diego, California.Read More Beat the Market (BTM) Rank™ 2.4 Analyst's Opinion Consensus RatingDexCom has received a consensus rating of Buy. The company's average rating score is 2.73, and is based on 16 buy ratings, 6 hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $319.24, DexCom has a potential downside of 15.7% from its current price of $378.70.Amount of Analyst CoverageDexCom has been the subject of 15 research reports in the past 90 days, demonstrating strong analyst interest in this stock. Previous Next 3.0 Community Rank Outperform VotesDexCom has received 851 “outperform” votes. (Add your “outperform” vote.)Underperform VotesDexCom has received 571 “underperform” votes. (Add your “underperform” vote.)Community SentimentDexCom has received 59.85% “outperform” votes from our community.MarketBeat's community ratings are surveys of what our community members think about DexCom and other stocks. Vote “Outperform” if you believe DXCM will outperform the S&P 500 over the long term. Vote “Underperform” if you believe DXCM will underperform the S&P 500 over the long term. You may vote once every thirty days. Previous Next 0.0 Dividend Strength Dividend YieldDexCom does not currently pay a dividend.Dividend GrowthDexCom does not have a long track record of dividend growth. Previous Next 1.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, DexCom insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $25,834,471.00 in company stock.Percentage Held by InsidersOnly 0.69% of the stock of DexCom is held by insiders.Percentage Held by Institutions97.08% of the stock of DexCom is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 1.3 Earnings and Valuation Earnings GrowthEarnings for DexCom are expected to grow by 37.22% in the coming year, from $2.23 to $3.06 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of DexCom is 238.18, which means that it is trading at a more expensive P/E ratio than the market average P/E ratio of about 15.59.Price to Earnings Ratio vs. SectorThe P/E ratio of DexCom is 238.18, which means that it is trading at a more expensive P/E ratio than the Medical sector average P/E ratio of about 25.41.Price to Book Value per Share RatioDexCom has a P/B Ratio of 39.28. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next Analyst Opinion: 2.4Community Rank: 3.0Dividend Strength: 0.0Insider Behavior: 1.0Valuation: 1.3 5 -4 -3 -2 -1 -Overall Beat the Market Rank™1.52 out of 5 stars Industry, Sector and Symbol Stock Exchange NASDAQ Industry Surgical & medical instruments Sub-IndustryHealth Care Equipment SectorMedical Current SymbolNASDAQ:DXCM Previous Symbol CUSIP25213110 CIK1093557 Webwww.dexcom.com Phone858-200-0200Debt Debt-to-Equity Ratio1.23 Current Ratio5.82 Quick Ratio5.41Price-To-Earnings Trailing P/E Ratio238.18 Forward P/E Ratio169.82 P/E GrowthN/A Sales & Book Value Annual Sales$1.48 billion Price / Sales23.69 Cash Flow$2.39 per share Price / Cash Flow158.26 Book Value$9.64 per share Price / Book39.28Profitability EPS (Most Recent Fiscal Year)$1.84 Net Income$101.10 million Net Margins9.24% Return on Equity26.44% Return on Assets9.50%Miscellaneous Employees3,900 Outstanding Shares92,345,000Market Cap$34.97 billion Next Earnings Date7/29/2020 (Estimated) OptionableOptionable NASDAQ:DXCM Rates by TradingView Receive DXCM News and Ratings via Email Sign-up to receive the latest news and ratings for DXCM and its competitors with MarketBeat's FREE daily newsletter. DexCom (NASDAQ:DXCM) Frequently Asked Questions How has DexCom's stock been impacted by COVID-19 (Coronavirus)? DexCom's stock was trading at $252.42 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization (WHO). Since then, DXCM shares have increased by 50.0% and is now trading at $378.70. View which stocks have been most impacted by Coronavirus. Do Wall Street analysts recommend investors buy shares of DexCom? 22 Wall Street analysts have issued "buy," "hold," and "sell" ratings for DexCom in the last year. There are currently 6 hold ratings and 16 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for DexCom. When is DexCom's next earnings date? DexCom is scheduled to release its next quarterly earnings announcement on Wednesday, July 29th 2020. View our earnings forecast for DexCom. How were DexCom's earnings last quarter? DexCom, Inc. (NASDAQ:DXCM) issued its quarterly earnings results on Tuesday, April, 28th. The medical device company reported $0.44 EPS for the quarter, beating analysts' consensus estimates of $0.15 by $0.29. The medical device company had revenue of $405.10 million for the quarter, compared to analysts' expectations of $358.34 million. DexCom had a net margin of 9.24% and a return on equity of 26.44%. The company's quarterly revenue was up 44.4% compared to the same quarter last year. During the same quarter in the prior year, the firm posted ($0.05) earnings per share. View DexCom's earnings history. What price target have analysts set for DXCM? 22 brokers have issued twelve-month price targets for DexCom's stock. Their forecasts range from $125.00 to $450.00. On average, they expect DexCom's stock price to reach $319.24 in the next twelve months. This suggests that the stock has a possible downside of 15.7%. View analysts' price targets for DexCom. What are Wall Street analysts saying about DexCom stock? Here are some recent quotes from research analysts about DexCom stock: 1. According to Zacks Investment Research, "Strong contributions from the Sensor and Transmitter segments remain key catalysts for DexCom. Further, solid guidance instills optimism in the stock. The glucose monitoring market presents significant commercial opportunity for DexCom. Opportunities in alternative markets such as the non-intensive diabetes management space, hospital, gestational, pre-diabetes and obesity are likely to provide DexCom a competitive edge in the MedTech space. DexCom exited the third quarter on a strong note, wherein both earnings and revenues beat the Zacks Consensus Estimate. Shares of the company have outperformed the industry in a year's time. Meanwhile, cutthroat competition in the market for blood & glucose monitoring devices remains a headwind." (1/8/2020) 2. Northland Securities analysts commented, "We present here a comparative assessment of 2.0 data readouts. Our global view is….we love Dexcom, but believe the story is going to be pressured on all fronts….top-line growth, margins, and market share. If this data is representative of the FDA submission (or part thereof), there is no doubt that Libre 2.0 will get an i" designation." (6/6/2019) Has DexCom been receiving favorable news coverage? News stories about DXCM stock have trended very positive recently, InfoTrie reports. The research group identifies negative and positive press coverage by monitoring more than six thousand news and blog sources in real-time. The firm ranks coverage of public companies on a scale of negative five to five, with scores nearest to five being the most favorable. DexCom earned a media sentiment score of 3.5 on InfoTrie's scale. They also assigned news coverage about the medical device company a news buzz of 0.0 out of 10, indicating that recent press coverage is extremely unlikely to have an impact on the company's share price in the near term. View the latest news aboutDexCom. Are investors shorting DexCom? DexCom saw a increase in short interest in the month of May. As of May 15th, there was short interest totaling 4,880,000 shares, an increase of 7.3% from the April 30th total of 4,550,000 shares. Based on an average daily volume of 1,840,000 shares, the days-to-cover ratio is presently 2.7 days. Currently, 5.4% of the shares of the stock are short sold. View DexCom's Current Options Chain. Who are some of DexCom's key competitors? Some companies that are related to DexCom include Abbott Laboratories (ABT), Medtronic (MDT), Stryker (SYK), Intuitive Surgical (ISRG), Becton Dickinson and (BDX), Boston Scientific (BSX), Edwards Lifesciences (EW), Baxter International (BAX), IDEXX Laboratories (IDXX), ResMed (RMD), Teleflex (TFX), Steris (STE), Hologic (HOLX), Masimo (MASI) and Insulet (PODD). View all competitors. What other stocks do shareholders of DexCom own? Based on aggregate information from My MarketBeat watchlists, some companies that other DexCom investors own include NVIDIA (NVDA), Alibaba Group (BABA), Paypal (PYPL), Netflix (NFLX), Advanced Micro Devices (AMD), salesforce.com (CRM), Vertex Pharmaceuticals (VRTX), Adobe (ADBE), ServiceNow (NOW) and Shopify (SHOP). Who are DexCom's key executives? DexCom's management team includes the following people: Mr. Kevin R. Sayer, Exec. Chairman, CEO & Pres (Age 61)Mr. Quentin S. Blackford, Exec. VP & CFO (Age 40)Mr. Steven R. Pacelli, Exec. VP of Strategy & Corp. Devel. (Age 47)Mr. Andrew K. Balo, Exec. VP of Clinical Affairs, Regulatory Strategies & Global Access (Age 71)Mr. Richard B. Doubleday, Exec. VP & Chief Commercial Officer (Age 56) What is DexCom's stock symbol? DexCom trades on the NASDAQ under the ticker symbol "DXCM." Who are DexCom's major shareholders? DexCom's stock is owned by many different retail and institutional investors. Top institutional shareholders include Baillie Gifford & Co. (5.23%), Jennison Associates LLC (2.92%), Wellington Management Group LLP (1.71%), Capital World Investors (1.68%), Geode Capital Management LLC (1.32%) and Blair William & Co. IL (1.23%). Company insiders that own DexCom stock include Andrew K Balo, Barbara Kahn, Donald Abbey, Eric Topol, Heather S Ace, Jacob Steven Leach, Jeffrey Moy, Jereme M Sylvain, Kevin R Sayer, Mark G Foletta, Nicholas Augustinos, Patrick Michael Murphy, Quentin S Blackford, Richard Alexander Collins, Richard Doubleday, Shelly Ramasamy Selvaraj, Steven R Altman, Steven Robert Pacelli and Terrance H Gregg. View institutional ownership trends for DexCom. Which institutional investors are selling DexCom stock? DXCM stock was sold by a variety of institutional investors in the last quarter, including Capital World Investors, Jennison Associates LLC, Mackenzie Financial Corp, KBC Group NV, Rockefeller Capital Management L.P., Fred Alger Management LLC, Ardevora Asset Management LLP, and APG Asset Management N.V.. Company insiders that have sold DexCom company stock in the last year include Andrew K Balo, Barbara Kahn, Donald Abbey, Heather S Ace, Jacob Steven Leach, Jeffrey Moy, Jereme M Sylvain, Kevin R Sayer, Mark G Foletta, Nicholas Augustinos, Patrick Michael Murphy, Quentin S Blackford, Richard Alexander Collins, Richard Doubleday, Shelly Ramasamy Selvaraj, Steven R Altman, and Steven Robert Pacelli. View insider buying and selling activity for DexCom. Which institutional investors are buying DexCom stock? DXCM stock was acquired by a variety of institutional investors in the last quarter, including Sands Capital Management LLC, Janus Henderson Group PLC, Sumitomo Mitsui Trust Holdings Inc., Russell Investments Group Ltd., Capital International Investors, Redmile Group LLC, Orbimed Advisors LLC, and Geode Capital Management LLC. View insider buying and selling activity for DexCom. How do I buy shares of DexCom? Shares of DXCM can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. What is DexCom's stock price today? One share of DXCM stock can currently be purchased for approximately $378.70. How big of a company is DexCom? DexCom has a market capitalization of $34.97 billion and generates $1.48 billion in revenue each year. The medical device company earns $101.10 million in net income (profit) each year or $1.84 on an earnings per share basis. DexCom employs 3,900 workers across the globe. What is DexCom's official website? The official website for DexCom is www.dexcom.com. How can I contact DexCom? DexCom's mailing address is 6340 SEQUENCE DRIVE, SAN DIEGO CA, 92121. The medical device company can be reached via phone at 858-200-0200 or via email at [email protected] This page was last updated on 6/2/2020 by MarketBeat.com Staff
